Development and Validation of Single Field Multi-Ion Particle Therapy Treatments

Benedikt Kopp, Stewart Mein, Ivana Dokic, Semi Harrabi, Till Tobias Böhlen, Thomas Haberer, Jürgen Debus, Amir Abdollahi, Andrea Mairani

Research output: Contribution to journalArticle

Abstract

Purpose: To develop and validate combined ion-beam with constant relative biological effectiveness (RBE) (CICR) particle therapy in single field arrangements for improved treatment efficacy, robustness, and normal tissue sparing. Methods and Materials: The PRECISE (PaRticle thErapy using single and Combined Ion optimization StratEgies) treatment planning system was developed to investigate clinical viability of CICR treatments. Single-field uniform dose (SFUD) with a single ion (proton [p], helium [He], or carbon [C]) and CICR (C-p and C-He) treatments were generated for 3 patient cases with a clinically prescribed dose of 3 Gy (RBE) per fraction. Spread-out Bragg peak plans were irradiated in homogenous and clinical-like settings using an anthropomorphic head phantom. A dosimetric and biological verification of CICRC-p treatments using a murine glioma cell line (GL261) was performed. Results: CICR treatment plans for the 3 patients presented highly uniform physical dose while reducing high dose-averaged linear energy transfer gradients compared with carbon ions alone. When considering uncertainty in tissue parameter (α/β)x assignment and RBE modeling, the CICRC-p treatment exhibited enhanced biophysical stability within the target volume, similar to protons alone. CICR treatments reduced dose to normal tissue surrounding the target, exhibiting similar or improved dosimetric features compared with SFUDHe. For both CICRC-p and SFUD treatments, measurements verified the planned dose in the target within ∼3%. Planned versus measured target RBE values were 1.38 ± 0.02 and 1.39 ± 0.07 (<1% deviation), respectively, for the CICRC-p treatment in heterogenous settings. Conclusions: Here, we demonstrate that by combining 2 (or more) ions in a single field arrangement, more robust biological and more conformal dose distributions can be delivered compared with conventional particle therapy treatment planning. This work constitutes the first dosimetric and biological verification of multi-ion particle therapy in homogeneous as well as heterogenous settings.

Original languageEnglish (US)
Pages (from-to)194-205
Number of pages12
JournalInternational Journal of Radiation Oncology Biology Physics
Volume106
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

therapy
Ions
dosage
Relative Biological Effectiveness
ions
Therapeutics
Helium
planning
helium
Protons
Carbon
linear energy transfer (LET)
protons
carbon
Linear Energy Transfer
cultured cells
viability
Glioma
ion beams
Uncertainty

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Development and Validation of Single Field Multi-Ion Particle Therapy Treatments. / Kopp, Benedikt; Mein, Stewart; Dokic, Ivana; Harrabi, Semi; Böhlen, Till Tobias; Haberer, Thomas; Debus, Jürgen; Abdollahi, Amir; Mairani, Andrea.

In: International Journal of Radiation Oncology Biology Physics, Vol. 106, No. 1, 01.01.2020, p. 194-205.

Research output: Contribution to journalArticle

Kopp, Benedikt ; Mein, Stewart ; Dokic, Ivana ; Harrabi, Semi ; Böhlen, Till Tobias ; Haberer, Thomas ; Debus, Jürgen ; Abdollahi, Amir ; Mairani, Andrea. / Development and Validation of Single Field Multi-Ion Particle Therapy Treatments. In: International Journal of Radiation Oncology Biology Physics. 2020 ; Vol. 106, No. 1. pp. 194-205.
@article{db4d94f14ee843c48389299a243ac600,
title = "Development and Validation of Single Field Multi-Ion Particle Therapy Treatments",
abstract = "Purpose: To develop and validate combined ion-beam with constant relative biological effectiveness (RBE) (CICR) particle therapy in single field arrangements for improved treatment efficacy, robustness, and normal tissue sparing. Methods and Materials: The PRECISE (PaRticle thErapy using single and Combined Ion optimization StratEgies) treatment planning system was developed to investigate clinical viability of CICR treatments. Single-field uniform dose (SFUD) with a single ion (proton [p], helium [He], or carbon [C]) and CICR (C-p and C-He) treatments were generated for 3 patient cases with a clinically prescribed dose of 3 Gy (RBE) per fraction. Spread-out Bragg peak plans were irradiated in homogenous and clinical-like settings using an anthropomorphic head phantom. A dosimetric and biological verification of CICRC-p treatments using a murine glioma cell line (GL261) was performed. Results: CICR treatment plans for the 3 patients presented highly uniform physical dose while reducing high dose-averaged linear energy transfer gradients compared with carbon ions alone. When considering uncertainty in tissue parameter (α/β)x assignment and RBE modeling, the CICRC-p treatment exhibited enhanced biophysical stability within the target volume, similar to protons alone. CICR treatments reduced dose to normal tissue surrounding the target, exhibiting similar or improved dosimetric features compared with SFUDHe. For both CICRC-p and SFUD treatments, measurements verified the planned dose in the target within ∼3{\%}. Planned versus measured target RBE values were 1.38 ± 0.02 and 1.39 ± 0.07 (<1{\%} deviation), respectively, for the CICRC-p treatment in heterogenous settings. Conclusions: Here, we demonstrate that by combining 2 (or more) ions in a single field arrangement, more robust biological and more conformal dose distributions can be delivered compared with conventional particle therapy treatment planning. This work constitutes the first dosimetric and biological verification of multi-ion particle therapy in homogeneous as well as heterogenous settings.",
author = "Benedikt Kopp and Stewart Mein and Ivana Dokic and Semi Harrabi and B{\"o}hlen, {Till Tobias} and Thomas Haberer and J{\"u}rgen Debus and Amir Abdollahi and Andrea Mairani",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2019.10.008",
language = "English (US)",
volume = "106",
pages = "194--205",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Development and Validation of Single Field Multi-Ion Particle Therapy Treatments

AU - Kopp, Benedikt

AU - Mein, Stewart

AU - Dokic, Ivana

AU - Harrabi, Semi

AU - Böhlen, Till Tobias

AU - Haberer, Thomas

AU - Debus, Jürgen

AU - Abdollahi, Amir

AU - Mairani, Andrea

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Purpose: To develop and validate combined ion-beam with constant relative biological effectiveness (RBE) (CICR) particle therapy in single field arrangements for improved treatment efficacy, robustness, and normal tissue sparing. Methods and Materials: The PRECISE (PaRticle thErapy using single and Combined Ion optimization StratEgies) treatment planning system was developed to investigate clinical viability of CICR treatments. Single-field uniform dose (SFUD) with a single ion (proton [p], helium [He], or carbon [C]) and CICR (C-p and C-He) treatments were generated for 3 patient cases with a clinically prescribed dose of 3 Gy (RBE) per fraction. Spread-out Bragg peak plans were irradiated in homogenous and clinical-like settings using an anthropomorphic head phantom. A dosimetric and biological verification of CICRC-p treatments using a murine glioma cell line (GL261) was performed. Results: CICR treatment plans for the 3 patients presented highly uniform physical dose while reducing high dose-averaged linear energy transfer gradients compared with carbon ions alone. When considering uncertainty in tissue parameter (α/β)x assignment and RBE modeling, the CICRC-p treatment exhibited enhanced biophysical stability within the target volume, similar to protons alone. CICR treatments reduced dose to normal tissue surrounding the target, exhibiting similar or improved dosimetric features compared with SFUDHe. For both CICRC-p and SFUD treatments, measurements verified the planned dose in the target within ∼3%. Planned versus measured target RBE values were 1.38 ± 0.02 and 1.39 ± 0.07 (<1% deviation), respectively, for the CICRC-p treatment in heterogenous settings. Conclusions: Here, we demonstrate that by combining 2 (or more) ions in a single field arrangement, more robust biological and more conformal dose distributions can be delivered compared with conventional particle therapy treatment planning. This work constitutes the first dosimetric and biological verification of multi-ion particle therapy in homogeneous as well as heterogenous settings.

AB - Purpose: To develop and validate combined ion-beam with constant relative biological effectiveness (RBE) (CICR) particle therapy in single field arrangements for improved treatment efficacy, robustness, and normal tissue sparing. Methods and Materials: The PRECISE (PaRticle thErapy using single and Combined Ion optimization StratEgies) treatment planning system was developed to investigate clinical viability of CICR treatments. Single-field uniform dose (SFUD) with a single ion (proton [p], helium [He], or carbon [C]) and CICR (C-p and C-He) treatments were generated for 3 patient cases with a clinically prescribed dose of 3 Gy (RBE) per fraction. Spread-out Bragg peak plans were irradiated in homogenous and clinical-like settings using an anthropomorphic head phantom. A dosimetric and biological verification of CICRC-p treatments using a murine glioma cell line (GL261) was performed. Results: CICR treatment plans for the 3 patients presented highly uniform physical dose while reducing high dose-averaged linear energy transfer gradients compared with carbon ions alone. When considering uncertainty in tissue parameter (α/β)x assignment and RBE modeling, the CICRC-p treatment exhibited enhanced biophysical stability within the target volume, similar to protons alone. CICR treatments reduced dose to normal tissue surrounding the target, exhibiting similar or improved dosimetric features compared with SFUDHe. For both CICRC-p and SFUD treatments, measurements verified the planned dose in the target within ∼3%. Planned versus measured target RBE values were 1.38 ± 0.02 and 1.39 ± 0.07 (<1% deviation), respectively, for the CICRC-p treatment in heterogenous settings. Conclusions: Here, we demonstrate that by combining 2 (or more) ions in a single field arrangement, more robust biological and more conformal dose distributions can be delivered compared with conventional particle therapy treatment planning. This work constitutes the first dosimetric and biological verification of multi-ion particle therapy in homogeneous as well as heterogenous settings.

UR - http://www.scopus.com/inward/record.url?scp=85076008943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076008943&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2019.10.008

DO - 10.1016/j.ijrobp.2019.10.008

M3 - Article

C2 - 31610250

AN - SCOPUS:85076008943

VL - 106

SP - 194

EP - 205

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -